Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicentre, proof-of-concept, observational study

References

• WHO. Coronavirus disease 2019 (COVID-2019) Situation report-146.
   Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–481. doi: 10.1016/S2213-2600(20)30079-5
   PubMed Web of Science ®Google Scholar
• Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395:683–684. doi: 10.1016/S0140-6736(20)30361-5
   PubMed Web of Science ®Google Scholar
• Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475. doi: 10.1016/S0140-6736(20)30317-2
   PubMed Web of Science ®Google Scholar
• Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically Ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197:757–767. doi: 10.1164/rccm.201706-1172OC
   PubMed Web of Science ®Google Scholar
• Short KR, Kroeze EJBV, Fouchier RAM, et al. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis. 2014;14:57–69. doi: 10.1016/S1473-3099(13)70286-X
   PubMed Web of Science ®Google Scholar
• Herold S, Becker C, Ridge KM, et al. Influenza virus-induced lung injury: pathogenesis and implications for treatment. Eur Respir J. 2015;45:1463–1478. doi: 10.1183/09031936.00186214
   PubMed Web of Science ®Google Scholar
• Chen J, Subbarao K. The Immunobiology of SARS. Annu Rev Immunol. 2007;25:443–472. doi: 10.1146/annurev.immunol.25.022106.141706
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–422. doi: 10.1016/S2213-2600(20)30076-X
   PubMed Web of Science ®Google Scholar
• Gralinski LE, Baric RS. Molecular pathology of emerging coronavirus infections. J Pathol. 2015;235:185–195. doi: 10.1002/path.4454
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39:529–539. doi: 10.1007/s00281-017-0629-x
   PubMed Web of Science ®Google Scholar
• WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance, 25 January 2020. World Health Organization; 2020. https://apps.who.int/iris/handle/10665/330854. License: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17:873–890. doi: 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
   PubMed Web of Science ®Google Scholar
• Shi J, Li Y, Zhou X, et al. Lactate dehydrogenase and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested case-control study. BMC Med. 2020;18:1–6. doi: 10.1186/s12916-020-01633-7
   PubMed Web of Science ®Google Scholar
• Lewis SR, Pritchard MW, Thomas CM, et al. Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst Rev. 2019. https://doi.org/10.1002/14651858.CD004477.pub3
   Web of Science ®Google Scholar
• Martin-Loeches I, Lisboa T, Rhodes A, et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1) v influenza A infection. Intensive Care Med. 2011;37:272–283. doi: 10.1007/s00134-010-2078-z
   PubMed Web of Science ®Google Scholar
• Ni Y, Chen G, Sun J, et al. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care. 2019;23:99. doi: 10.1186/s13054-019-2395-8
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun W, Svendsen ER, et al. Do corticosteroids reduce the mortality of influenza A (H1N1) infection? A meta-analysis. Crit Care. 2015;19:46. doi: 10.1186/s13054-015-0764-5
   PubMed Web of Science ®Google Scholar
• Han K, Ma H, An X, et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis. 2011;53:326–333. doi: 10.1093/cid/cir398
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with covid-19 – preliminary Report. N Engl J Med. 2020. https://www.nejm.org/doi/10.1056/NEJMoa2021436?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
   Web of Science ®Google Scholar
• Lee N, Chan KA, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31:304–309. doi: 10.1016/j.jcv.2004.07.006
   PubMed Web of Science ®Google Scholar